1700001N15Rik Inhibitors
Chemical inhibitors of the protein 1700001N15Rik employ various mechanisms to impede its function within cellular signaling pathways. Wortmannin and LY294002 are two such inhibitors that directly target the phosphoinositide 3-kinase (PI3K) pathway, a crucial signaling route that 1700001N15Rik is a part of. By inhibiting PI3K, these chemicals prevent the activation of downstream components, such as AKT, ultimately leading to a suppression of 1700001N15Rik activity due to its reliance on PI3K/AKT for activation. Similarly, Triciribine specifically inhibits AKT phosphorylation, which is another step critical for the activation of 1700001N15Rik, thereby limiting its functional capacity within the cell.
Additional inhibitors, such as Rapamycin, Staurosporine, and Erlotinib, affect different aspects of the pathways that involve 1700001N15Rik. Rapamycin selectively inhibits mammalian target of rapamycin (mTOR), a component of cell growth and proliferation pathways that 1700001N15Rik is associated with. This inhibition holds back the function of 1700001N15Rik by targeting mTOR's role in the pathway. Staurosporine, a broad-spectrum protein kinase inhibitor, can impede the action of multiple kinases that would typically phosphorylate and thereby activate 1700001N15Rik. Erlotinib and Gefitinib, both EGFR tyrosine kinase inhibitors, obstruct the epidermal growth factor receptor (EGFR) pathway, under which 1700001N15Rik operates, by preventing downstream signaling cascades. Furthermore, the chemicals PD98059, U0126, SP600125, and SB203580 disrupt MAP kinase pathways by inhibiting MEK, JNK, and p38 MAP kinase, respectively. These pathways are integral to the regulation of cellular processes such as proliferation, stress response, and apoptosis, all of which 1700001N15Rik may influence. By halting the function of these kinases, the inhibitors can suppress the activity of 1700001N15Rik if it is a part of or regulated by these signaling routes.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a potent phosphoinositide 3-kinase (PI3K) inhibitor. Since 1700001N15Rik is a part of PI3K signaling, inhibition of PI3K by Wortmannin would lead to the downstream suppression of 1700001N15Rik activity. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is another inhibitor of PI3K, leading to the suppression of the AKT signaling pathway. Given that 1700001N15Rik operates within this pathway, LY294002 can inhibit its functional activity by preventing its activation via PI3K/AKT. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin selectively inhibits mTOR (mammalian target of rapamycin), which is involved in cell growth and proliferation. As 1700001N15Rik is part of the mTOR signaling pathway, Rapamycin would inhibit the function of 1700001N15Rik by inhibiting mTOR. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a non-selective protein kinase inhibitor. It inhibits a broad range of kinases which would include those that phosphorylate 1700001N15Rik, leading to the inhibition of its function. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $94.00 $227.00 | 30 | |
PP2 is an inhibitor of Src family kinases. By inhibiting these kinases, it would disrupt signaling pathways that regulate cell proliferation and survival where 1700001N15Rik may be functionally active, thereby inhibiting the protein’s activity. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is a selective inhibitor of MEK, which prevents the activation of ERK. As 1700001N15Rik is regulated by the MAPK/ERK pathway, PD98059 inhibits the function of 1700001N15Rik by blocking this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is also a MEK inhibitor that blocks the MAPK/ERK pathway, thus inhibiting the activity of 1700001N15Rik by preventing upstream activation signals from reaching it. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), part of the MAP kinase pathway involved in cell stress and apoptosis. Inhibiting JNK can suppress the functional activity of 1700001N15Rik if JNK is upstream of this protein. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 inhibits p38 MAP kinase, which is involved in cellular responses to cytokines and stress. By inhibiting p38, the functional activity of 1700001N15Rik is inhibited if it is a downstream target. | ||||||
Erlotinib, Free Base | 183321-74-6 | sc-396113 sc-396113A sc-396113B sc-396113C sc-396113D | 500 mg 1 g 5 g 10 g 100 g | $87.00 $135.00 $293.00 $505.00 $3827.00 | 42 | |
Erlotinib is an EGFR tyrosine kinase inhibitor. By inhibiting EGFR, it prevents activation of downstream signaling cascades that include 1700001N15Rik, thus inhibiting the protein's function. | ||||||